Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +47.16%
#3 Pons Pons +28.18%
#4 Non-Playable Coin Non-Playable Coin +22.05%
#5 OriginTrail OriginTrail +20.43%
#6 龙虾 (Lobster) 龙虾 (Lobster) +19.81%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.68%
#8 ApeX ApeX +18.60%
#9 Zora Zora +18.30%
#10 Morpho Morpho +17.03%
Coin of the day
Smilek to the Bank Smilek to the Bank
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
Clasificación en acciones #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Precio por acción
$2.10
Última sincronización: 2026-08-21
Capitalización bursátil
$104.43M
Cambio (1 día)
-2.10%
Cambio (1 año)
-
País
US
Comercio Polaryx Therapeutics, Inc. Common Stock (PLYX)

Categoría

Healthcare
Ganancias de Polaryx Therapeutics, Inc. Common Stock (PLYX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Polaryx Therapeutics, Inc. Common Stock, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Polaryx Therapeutics, Inc. Common Stock desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH